{"DataElement":{"publicId":"58258","version":"3","preferredName":"Chronic Myelogenous Leukemia Clinical Hematology Progression Classification Specify","preferredDefinition":"a text field to describe a disease category showing an increase in severity for a chronic myeloproliferative disorder based on evidence from physical exam or analysis of blood.","longName":"CML_C_HM_PR_CLA_SPEC","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2010327","version":"3","preferredName":"Chronic Myelogenous Leukemia Clinical Hematology Progression Classification","preferredDefinition":"related to the disease category showing an increase in severity for chronic myeloproliferative disorder characterized by neutrophilic leukocytosis from evidence by physical exam or analysis of blood.","longName":"CML_C_HMT_PROG_CLASS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2500393","version":"1","preferredName":"CML","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","longName":"C3174","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65B1-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2500394","version":"1","preferredName":"Clinical Hematology Progression Classification","preferredDefinition":"Having to do with the examination and treatment of patients.:Hematology; the branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.:Progression; advancement in extent or severity.:Classification; the grouping of things into classes or categories.","longName":"C25398:C16673:C25331:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hematology","conceptCode":"C16673","definition":"The branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Progression","conceptCode":"C25331","definition":"Progression; advancement in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65C4-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995927D-C24A-5D0E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"revised and updated to provide consistent naming of DECs using current EVS terms","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018786","version":"1","preferredName":"Disease Response Specify","preferredDefinition":"the free-text field to specify an aspect of disease response.","longName":"DZ_RESP_SPEC","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184338","version":"1","preferredName":"Specify","preferredDefinition":"Specify; be specific about something; define clearly.","longName":"Specify","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-2084-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8A14E97-9CFE-5BE2-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-03-11","modifiedBy":"CAMPBELB","dateModified":"2005-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811955","version":"1","longName":"Follow-up","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811797","version":"1","longName":"CML Prev Untreated","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other specify","type":"Preferred Question Text","description":"Other specify","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Hematologic Progression CML Classification","url":null,"context":"CTEP"}],"origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"199676A3-7E40-59F5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"REEVESD","dateModified":"2011-04-05","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}